# TH Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The human *TH* gene, located on chromosome 11p15.5, encodes tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine biosynthesis, catalyzing the conversion of L-tyrosine to L-DOPA, the precursor for dopamine, norepinephrine, and epinephrine.
- Mutations in the *TH* gene cause autosomal recessive disorders, primarily Segawa syndrome (dopa-responsive dystonia, DRD) and infantile-onset encephalopathy, characterized by neurological deficits and a dramatic response to L-DOPA therapy.
- TH enzyme activity is tightly regulated by transcriptional factors (e.g., CREB, NURR1) and post-translational modifications, particularly phosphorylation at Ser19, Ser31, and Ser40, which modulate enzyme activity and response to feedback inhibition by catecholamines.
- The *TH* gene exhibits alternative splicing, generating at least four human mRNA isoforms (TH1-TH4) with tissue-specific expression patterns, influencing regulatory mechanisms and functional outcomes.
- Polymorphisms within the *TH* gene, particularly the intron 1 tetranucleotide repeat (VNTR), have been associated with increased susceptibility to neuropsychiatric disorders like schizophrenia and essential hypertension, suggesting a role in modulating catecholamine pathway function and sympathetic tone.
- The protein structure of TH comprises an N-terminal regulatory domain, a catalytic domain housing the iron cofactor and BH4 binding site, and a C-terminal tetramerization domain essential for functional quaternary structure.

---

## Executive Summary & Key Metadata

Tyrosine hydroxylase (TH) is the rate-limiting enzyme in catecholamine biosynthesis, catalyzing the conversion of L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA). This reaction is the first and committed step in the production of dopamine, norepinephrine, and epinephrine—neurotransmitters and hormones that govern motor control, cognition, reward, autonomic function, and endocrine signaling. The human TH gene is located on chromosome 11p15.5, a region of significant genomic complexity that also harbors the insulin (INS) and insulin-like growth factor 2 (IGF2) genes. TH is expressed predominantly in the central nervous system (substantia nigra, ventral tegmental area, locus coeruleus), sympathetic ganglia, adrenal medulla, and specific peripheral tissues. Mutations in TH cause autosomal recessive Segawa syndrome (dopa-responsive dystonia, DRD) and infantile-onset encephalopathy with severe neurological deficits. Beyond its canonical enzymatic role, TH is a critical node in neurodevelopmental plasticity, stress responses, and has been implicated in neuropsychiatric disorders, hypertension, and Parkinson's disease (PD) pathogenesis.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | TH |
| **UniProt Accession** | P07101 |
| **Representative PDB ID** | 2XSN (catalytic domain, human) |
| **Chromosomal Locus** | 11p15.5 (GRCh38: chr11:2,163,615–2,171,157) |
| **Primary Molecular Function** | Tyrosine 3-monooxygenase (EC 1.14.16.2); rate-limiting step in catecholamine synthesis |
| **Disease & Pathology Associations** | Autosomal recessive Segawa syndrome (DYT5b), TH-deficient infantile encephalopathy, Parkinson's disease susceptibility, essential hypertension, neuropsychiatric disorders |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Gene Architecture

The human TH gene spans approximately 7.5 kilobases (kb) on the short arm of chromosome 11 (11p15.5), a gene-dense, imprinted region with complex regulatory architecture. The gene is oriented in the same transcriptional direction as the adjacent INS and IGF2 genes, forming the IGF2-INS-TH gene cluster—a locus that has been extensively studied for its association with cardiovascular risk traits, type 2 diabetes, and growth phenotypes [1]. The TH gene comprises 14 exons and 13 introns, with the translation initiation codon located in exon 1 and the stop codon in exon 14. The primary transcript undergoes alternative splicing to generate at least four distinct mRNA isoforms in humans (TH1–TH4), which differ in their 3' coding regions due to alternative exon usage [2].

The core promoter region of TH lacks a canonical TATA box but contains a GC-rich region with multiple Sp1 binding sites, consistent with its expression in both neuronal and endocrine tissues. The 5' flanking region contains several cis-acting regulatory elements, including an AP-1 site, a cyclic AMP response element (CRE), and a hypoxia-responsive element (HRE). The CRE is critical for basal and inducible transcription, mediating responses to cAMP-elevating agents, BDNF, and depolarization [3]. The first intron harbors a polymorphic tetranucleotide repeat (TCAT)n, which has been used extensively in genetic association studies [4]. This intronic VNTR (variable number tandem repeat) has been associated with schizophrenia susceptibility and altered catecholamine pathway function [5].

### 1.2 Alternative Splicing and Isoform Diversity

Alternative splicing of TH pre-mRNA generates isoforms with distinct C-terminal sequences. In humans, four isoforms (TH1–TH4) arise from the differential inclusion of exons 13 and 14. TH1 is the predominant isoform in the brain, while TH2–TH4 show tissue-specific expression patterns, with TH2 enriched in the adrenal medulla and TH3/TH4 in peripheral tissues. The functional significance of these isoforms relates to differential regulation by phosphorylation: the C-terminal region contains serine residues (Ser19, Ser31, Ser40) that are substrates for various kinases, and isoform-specific differences in these regulatory domains modulate enzyme activity and stability. The rat TH gene produces a single isoform, whereas the human gene's complexity reflects evolutionary divergence in catecholaminergic regulation [6].

### 1.3 Promoter Architecture and Transcriptional Regulation

The TH promoter integrates multiple signaling pathways. Key regulatory elements include:

- **CRE (cAMP Response Element)**: Located approximately 45 bp upstream of the transcription start site, this element binds CREB (cAMP response element-binding protein) and is essential for basal transcription. Phosphorylation of CREB at Ser133 by PKA, CaMKIV, or ERK pathways activates TH transcription [7].
- **AP-1 Site**: Binds Fos/Jun heterodimers and mediates responses to growth factors and stress signals.
- **E-box Elements**: Recognized by basic helix-loop-helix (bHLH) transcription factors, including the neuronal-specific factor NURR1 (NR4A2), which is critical for dopaminergic neuron development and maintenance.
- **GATA Elements**: Bind GATA-2 and GATA-3 transcription factors, which are essential for catecholaminergic neuron specification [8].
- **HIF-1α Binding Site**: Mediates hypoxia-induced TH upregulation, relevant to adaptation to low oxygen conditions.

Enhancer elements have been identified in intron 1 and in the 3' flanking region. The intron 1 enhancer contains binding sites for AP-2, which cooperates with CREB to drive high-level expression in catecholaminergic cells. Chromatin immunoprecipitation (ChIP) studies have demonstrated that histone acetylation at the TH promoter correlates with transcriptional activation, and that the histone acetyltransferase CBP/p300 is recruited to the promoter upon cAMP stimulation [3].

### 1.4 Epigenetic Regulation

DNA methylation at CpG islands within the TH promoter regulates tissue-specific expression. The promoter is hypomethylated in catecholaminergic tissues but hypermethylated in non-neuronal cells, contributing to silencing. Environmental factors, including early-life stress and exposure to endocrine-disrupting chemicals, can alter methylation patterns at the TH locus, with potential long-term consequences for catecholamine function [9]. Histone modifications, particularly H3K4me3 at the promoter and H3K27ac at enhancers, mark the active TH locus in dopaminergic neurons.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The human TH protein (UniProt P07101) is composed of 497 amino acids (TH1 isoform) with a molecular weight of approximately 55.6 kDa. The protein folds into three functional domains:

1. **N-terminal Regulatory Domain (residues 1–165)**: This region contains the serine phosphorylation sites (Ser19, Ser31, Ser40) that modulate enzyme activity. The N-terminus also contains a 33-residue sequence that is cleaved in some isoforms, potentially affecting subcellular localization. Structural studies show that this domain is largely disordered in solution but adopts a more ordered conformation upon phosphorylation, facilitating interaction with 14-3-3 proteins.

2. **Catalytic Domain (residues 166–455)**: This is the core enzymatic domain, belonging to the aromatic amino acid hydroxylase (AAAH) superfamily. It adopts a predominantly α-helical fold with a central seven-stranded β-sheet. The catalytic domain contains the active site, which coordinates the non-heme iron (Fe²⁺) cofactor and binds the substrates L-tyrosine, molecular oxygen, and the cofactor tetrahydrobiopterin (BH4). Key catalytic residues include:
   - **His331, His336, and Glu376**: These residues coordinate the iron atom in a 2-His-1-carboxylate facial triad, a hallmark of non-heme iron-dependent oxygenases.
   - **Tyr371**: Participates in substrate binding and stabilizes the transition state.
   - **Arg316 and Arg318**: Form hydrogen bonds with the carboxylate group of L-tyrosine.

3. **C-terminal Tetramerization Domain (residues 456–497)**: This domain mediates the assembly of TH into a homotetramer, which is the functional oligomeric state. The tetramerization domain forms a four-helix bundle, with each monomer contributing one α-helix. Tetramerization is essential for catalytic activity and stability; mutations disrupting this domain cause loss of function and disease [2].

### 2.2 Quaternary Structure and Catalytic Mechanism

The TH holoenzyme exists as a homotetramer (dimer of dimers). Each monomer binds one Fe²⁺ ion and one BH4 molecule. The catalytic mechanism involves:

1. **Substrate Binding**: L-tyrosine binds in the active site pocket, positioned adjacent to the iron center.
2. **Oxygen Activation**: Molecular oxygen binds to the iron, forming an Fe³⁺-superoxo intermediate.
3. **BH4 Cofactor Function**: BH4 donates electrons to reduce the iron-oxygen complex, generating an Fe⁴⁺-oxo species that hydroxylates the aromatic ring of tyrosine at the meta position.
4. **Product Release**: The reaction yields L-DOPA, water, and dihydrobiopterin (BH2), which is recycled to BH4 by dihydropteridine reductase (DHPR).

The enzyme exhibits positive cooperativity for BH4 binding and is subject to feedback inhibition by dopamine and norepinephrine, which compete with BH4 for binding. This end-product inhibition is a critical regulatory mechanism that maintains catecholamine homeostasis.

### 2.3 Structural Insights from Crystallography

High-resolution crystal structures of the human TH catalytic domain (PDB: 2XSN) have revealed the detailed architecture of the active site. The iron center is coordinated by His331, His336, and Glu376, with three water molecules completing the octahedral coordination sphere in the resting state. Substrate binding displaces two water molecules, allowing oxygen to coordinate. The BH4 binding site is adjacent to the iron, forming a pterin-binding pocket that is conserved across the AAAH family. Mutations at residues within this pocket (e.g., R233H, R316C) disrupt cofactor binding and cause severe enzymatic deficiency [2].

[Interactive 3D Protein Visualizer: Load TH (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P07101)

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Catecholamine Biosynthesis Pathway

TH catalyzes the first and rate-limiting step in catecholamine synthesis:

**L-Tyrosine → L-DOPA → Dopamine → Norepinephrine → Epinephrine**

The downstream enzymes include aromatic L-amino acid decarboxylase (AADC), dopamine β-hydroxylase (DBH), and phenylethanolamine N-methyltransferase (PNMT). TH activity is the primary control point for the entire pathway; modulation of TH expression or activity directly impacts catecholamine levels in the brain and periphery [10].

### 3.2 Regulation of TH Activity

TH is regulated at multiple levels:

**Transcriptional Regulation**: As described in Section 1.3, TH transcription is controlled by a complex network of transcription factors and signaling pathways. BDNF activates TH transcription via the TrkB receptor, leading to ERK-dependent phosphorylation of CREB [3]. Glucocorticoids, through the glucocorticoid receptor, also upregulate TH expression in the adrenal medulla. Short-chain fatty acids (SCFAs) such as propionic and butyric acid, produced by gut microbiota, induce TH gene expression via ERK-dependent CREB phosphorylation, linking the microbiome to catecholamine function [7, 11].

**Post-translational Regulation**: TH activity is modulated by phosphorylation at three serine residues:
- **Ser19**: Phosphorylated by CaMKII and MAPKAPK-2. This site regulates the interaction with 14-3-3 proteins, which stabilize the active conformation.
- **Ser31**: Phosphorylated by ERK1/2 and CDK5. Phosphorylation at this site increases enzyme activity by approximately 2-fold.
- **Ser40**: Phosphorylated by PKA, PKG, PKC, and CaMKII. This is the most critical regulatory site; phosphorylation at Ser40 relieves feedback inhibition by catecholamines and increases catalytic activity by 3- to 4-fold.

Dephosphorylation by protein phosphatases (PP2A, PP2C) reverses these effects. The phosphorylation state of TH is dynamically regulated by neuronal activity, hormonal signals, and pharmacological agents.

**Allosteric Regulation**: TH is subject to feedback inhibition by dopamine, norepinephrine, and epinephrine, which compete with BH4 for binding to the active site. This inhibition is relieved by phosphorylation at Ser40, which induces a conformational change that reduces catecholamine affinity. The enzyme is also activated by polyanions such as heparin and phosphatidylinositol, which may stabilize the tetrameric form.

### 3.3 Protein-Protein Interactions

TH interacts with several proteins that modulate its function:

- **14-3-3 Proteins**: Bind to phosphorylated Ser19 and stabilize the active conformation of TH, protecting it from dephosphorylation and proteolytic degradation.
- **α-Synuclein (SNCA)**: Interacts with TH and regulates its activity. In Parkinson's disease, α-synuclein aggregation leads to TH downregulation and dopaminergic neuron death [12].
- **Parkin (PRKN)**: An E3 ubiquitin ligase that ubiquitinates TH, targeting it for proteasomal degradation. Loss-of-function mutations in Parkin cause autosomal recessive juvenile parkinsonism, associated with TH accumulation and dopaminergic dysfunction.
- **DJ-1 (PARK7)**: A redox-sensitive chaperone that interacts with TH and protects it from oxidative damage.

### 3.4 Signaling Pathways Involving TH

TH is both a downstream target and a modulator of multiple signaling cascades:

**cAMP/PKA Pathway**: Activation of Gs-coupled receptors (e.g., D1 dopamine receptors, β-adrenergic receptors) increases cAMP, activating PKA, which phosphorylates CREB and TH at Ser40. This pathway mediates the acute and chronic regulation of catecholamine synthesis.

**MAPK/ERK Pathway**: Growth factors (BDNF, NGF) activate the Ras-Raf-MEK-ERK cascade, leading to phosphorylation of CREB and TH at Ser31. This pathway is critical for neuronal differentiation and survival [3].

**Ca²⁺/CaMK Pathway**: Depolarization-induced Ca²⁺ influx activates CaMKII, which phosphorylates TH at Ser19 and Ser40. NMDA receptor activation also suppresses TH transcription via Ca²⁺-dependent mechanisms, providing a negative feedback loop [3].

**HIF-1α Pathway**: Hypoxia stabilizes HIF-1α, which binds to the HRE in the TH promoter and upregulates TH expression. This adaptation is important for survival under low oxygen conditions.

```mermaid
sequenceDiagram
    participant Ligand as "Extracellular Ligand (BDNF, Dopamine, Glucocorticoid)"
    participant Receptor as "Receptor (TrkB, D1R, GR)"
    participant Kinase as "Kinase (PKA, ERK, CaMKII)"
    participant CREB as "CREB"
    participant THgene as "TH Gene"
    participant THprotein as "TH Protein"
    participant Catecholamine as "Catecholamines (DA, NE, Epi)"
    Ligand->>Receptor: Binding
    Receptor->>Kinase: Activation
    Kinase->>CREB: Phosphorylation (Ser133)
    Kinase->>THprotein: Phosphorylation (Ser19/31/40)
    CREB->>THgene: Transcriptional Activation
    THgene->>THprotein: Increased Synthesis
    THprotein->>Catecholamine: L-DOPA Production
    Catecholamine-->>THprotein: Feedback Inhibition (competes with BH4)
    Catecholamine-->>Receptor: Autoreceptor Activation (D2)
```

### 3.5 Tissue-Specific Functions

**Central Nervous System**: TH is expressed in dopaminergic neurons of the substantia nigra pars compacta (A9), ventral tegmental area (A10), and retrorubral field (A8), as well as noradrenergic neurons of the locus coeruleus (A6) and lateral tegmental field. TH expression in these regions is essential for motor control, reward processing, motivation, and attention [12].

**Peripheral Nervous System**: TH is expressed in sympathetic ganglia and adrenal chromaffin cells, where it regulates norepinephrine and epinephrine synthesis. TH activity in the adrenal medulla is induced by stress and glucocorticoids.

**Non-neuronal Tissues**: TH is expressed in the gut (enteric neurons), pancreas (β-cells), and immune cells (T lymphocytes). In T cells, TH-derived dopamine modulates immune responses, and TH expression is regulated during T helper cell differentiation [8, 13].

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 TH Deficiency (Segawa Syndrome / Dopa-Responsive Dystonia)

Autosomal recessive mutations in TH cause a spectrum of disorders ranging from mild DRD (Segawa syndrome, DYT5b) to severe infantile-onset encephalopathy with progressive neurological deterioration [2, 14]. Over 50 pathogenic mutations have been identified, including missense, nonsense, frameshift, and splice-site variants.

**Clinical Phenotypes**:

1. **Type A (Mild DRD)**: Presents in childhood with gait disturbance, dystonia, and tremor. Symptoms show diurnal fluctuation (worse in the evening, improved in the morning). Patients respond dramatically to low-dose L-DOPA therapy.

2. **Type B (Severe Encephalopathy)**: Presents in infancy with hypotonia, developmental delay, oculogyric crises, and autonomic dysfunction. May progress to parkinsonism, spasticity, and intellectual disability. Response to L-DOPA is variable and may require higher doses.

3. **Type C (Intermediate)**: Presents with a combination of dystonia and mild cognitive impairment.

**Hotspot Mutations**:

| **Mutation** | **Protein Change** | **Domain** | **Clinical Severity** | **Mechanism** |
|---|---|---|---|---|
| c.457C>T | R233H | Catalytic | Severe (Type B) | Disrupts BH4 binding |
| c.698G>A | R233Q | Catalytic | Moderate | Reduces catalytic activity |
| c.943C>T | R316C | Catalytic | Severe | Disrupts substrate binding |
| c.1124G>A | R375H | Catalytic | Severe | Disrupts iron coordination |
| c.1192C>T | R398W | Catalytic | Moderate | Reduces protein stability |
| c.1348C>T | R450C | Tetramerization | Mild (Type A) | Disrupts tetramer assembly |
| c.1360C>T | R454C | Tetramerization | Mild | Reduces tetramer stability |

The R233H mutation, located in the BH4 binding pocket, is among the most common pathogenic variants and causes severe enzyme deficiency [2]. Functional studies using recombinant TH have demonstrated that R233H reduces catalytic activity to less than 5% of wild-type levels and disrupts BH4 binding. The R316C mutation, affecting a residue critical for substrate binding, similarly causes profound loss of function.

### 4.2 Parkinson's Disease

While TH mutations are not a common cause of sporadic PD, TH is central to PD pathogenesis. Post-mortem studies show a marked reduction in TH immunoreactivity in the substantia nigra of PD patients, reflecting dopaminergic neuron loss. TH expression is also reduced in the striatum, where dopaminergic terminals degenerate. Polymorphisms in the TH gene, including the intron 1 VNTR, have been investigated as risk factors for PD, with conflicting results [15]. Haplotype analysis of the IGF2-INS-TH cluster has suggested that specific haplotypes may modulate PD risk, potentially through effects on TH expression or linkage disequilibrium with other susceptibility variants [15].

### 4.3 Essential Hypertension

The TH intron 1 VNTR has been associated with essential hypertension in the Northern Chinese Han population [16]. The VNTR is located in a region that may influence TH expression or mRNA stability. Individuals carrying certain repeat alleles show altered catecholamine levels and increased sympathetic tone, contributing to blood pressure elevation. The IGF2-INS-TH cluster has also been linked to cardiovascular risk traits, including blood pressure and lipid profiles [1].

### 4.4 Neuropsychiatric Disorders

TH polymorphisms have been studied in schizophrenia, attention-deficit/hyperactivity disorder (ADHD), and bipolar disorder. The intron 1 VNTR has been associated with disturbances in the catecholamine pathway in schizophrenia [5]. In canine models, TH intron 4 repeat polymorphisms are associated with activity-impulsivity and inattention in German Shepherd Dogs and Siberian Huskies, suggesting conserved effects on behavior [1, 17]. These findings support a role for TH in modulating impulsivity and attention across species.

### 4.5 Cancer

TH expression is altered in several cancers, particularly neuroendocrine tumors. Pheochromocytomas and neuroblastomas, which derive from catecholaminergic cells, express high levels of TH. TH expression is used as a diagnostic marker for these tumors and correlates with catecholamine production. In other cancers, TH may play a role in tumor progression through dopamine-mediated signaling. However, the direct role of TH mutations in cancer is limited, and the gene is not a major cancer driver [2].

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Effects on TH Expression

Several viruses modulate TH expression as part of their pathogenic mechanisms:

**Herpes Simplex Virus (HSV)**: HSV infection of sympathetic neurons can alter TH expression, potentially contributing to autonomic dysfunction during reactivation.

**Human Immunodeficiency Virus (HIV)**: HIV-associated neurocognitive disorders (HAND) are associated with dopaminergic dysfunction. HIV proteins, including Tat and gp120, can downregulate TH expression in dopaminergic neurons, contributing to motor and cognitive deficits. The Th1-Th2 hypothesis of HIV infection also implicates catecholamine signaling in immune dysregulation [3].

**Influenza Virus**: Experimental models suggest that influenza virus infection during neurodevelopment can lead to long-term reductions in TH expression, potentially increasing susceptibility to neuropsychiatric disorders.

### 5.2 Bacterial Interactions

**Gut Microbiota**: Bacterial metabolites, including short-chain fatty acids (SCFAs) such as propionic and butyric acid, modulate TH gene expression in enteric neurons and the brain [7, 11]. SCFAs activate ERK-dependent CREB phosphorylation, increasing TH transcription. This gut-brain axis may be relevant to autism spectrum disorders, where altered gut microbiota and catecholamine dysfunction have been observed [11].

**Rhodococcus ruber**: This bacterium, which contains a TH-like gene, has been engineered for biotechnological applications using CRISPR/Cas9 genome editing [4]. While not directly relevant to human disease, this work highlights the evolutionary conservation of TH across species.

### 5.3 Viral Vectors for Gene Therapy

Recombinant adeno-associated viruses (AAV) and lentiviruses are used to deliver TH cDNA for gene therapy in Parkinson's disease models [5, 6]. AAV vectors encoding TH, often in combination with AADC and GCH1 (GTP cyclohydrolase I), have shown long-term expression and phenotypic correction in primate models of PD [5]. However, immune responses to viral vectors and transgene products can limit efficacy [7]. Overcoming the blood-brain barrier remains a major challenge for systemic gene therapy approaches [8].

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 L-DOPA (Levodopa)

L-DOPA is the immediate product of TH and the gold-standard treatment for TH deficiency and Parkinson's disease. By bypassing the TH-catalyzed step, L-DOPA replenishes dopamine in the striatum. In TH-deficient patients, L-DOPA therapy can dramatically improve symptoms, particularly in mild forms of DRD [2, 14]. However, long-term L-DOPA use is associated with motor fluctuations and dyskinesias.

### 6.2 Tetrahydrobiopterin (BH4) and Analogues

BH4 is the essential cofactor for TH. In patients with TH mutations that impair BH4 binding, supplementation with BH4 (sapropterin dihydrochloride) may partially restore enzyme activity. However, the efficacy of BH4 therapy in TH deficiency is limited, as many mutations cause structural disruption beyond cofactor binding. BH4 is also used in the treatment of phenylketonuria (PKU), where it acts as a pharmacological chaperone for phenylalanine hydroxylase.

### 6.3 TH Inhibitors

**α-Methyl-p-tyrosine (AMPT)**: A competitive inhibitor of TH that blocks catecholamine synthesis. AMPT is used clinically to treat pheochromocytoma (catecholamine-secreting tumors) and in research to deplete catecholamines. It has also been investigated as an adjunct in the treatment of cocaine addiction.

**NSD-1015**: An aromatic amino acid decarboxylase inhibitor used in research to measure TH activity in vivo by preventing the conversion of L-DOPA to dopamine.

### 6.4 Gene Therapy

AAV-mediated delivery of TH cDNA is a promising approach for Parkinson's disease. Clinical trials have evaluated AAV2-TH, AAV2-AADC, and AAV2-GCH1 vectors, with some showing modest improvements in motor function [5]. However, the complexity of PD pathology, which involves multiple neurotransmitter systems, has limited the efficacy of single-gene approaches. Combination therapy with TH, AADC, and GCH1 is being explored to achieve more complete restoration of dopamine synthesis [10].

### 6.5 CRISPR/Cas9 Genome Editing

CRISPR/Cas9 technology offers the potential to correct pathogenic TH mutations. Preclinical studies have demonstrated efficient gene editing in dopaminergic neurons, and delivery systems using silica nanocapsules or AAV vectors are being developed to cross the blood-brain barrier [8]. Challenges include achieving sufficient editing efficiency in post-mitotic neurons and avoiding off-target effects.

### 6.6 Pharmacogenomic Considerations

TH polymorphisms may influence responses to dopaminergic drugs. The intron 1 VNTR has been associated with differential responses to antipsychotics and stimulants. In dogs, TH genotypes predict responses to behavioral interventions, suggesting that TH variation may modulate drug efficacy [1, 17]. Personalized approaches to L-DOPA dosing in TH deficiency may benefit from genotyping to predict treatment response.

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 7054 | https://www.ncbi.nlm.nih.gov/gene/7054 |
| Ensembl | ENSG00000123472 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000123472 |
| UniProt | P07101 | https://www.uniprot.org/uniprotkb/P07101 |
| RCSB PDB | 2XSN | https://www.rcsb.org/structure/2XSN |
| OMIM | 191290 | https://www.omim.org/entry/191290 |
| ClinVar | TH | https://www.ncbi.nlm.nih.gov/clinvar/?term=TH%5Bgene%5D |
| GeneCards | TH | https://www.genecards.org/cgi-bin/carddisp.pl?gene=TH |
| STRING | P07101 | https://string-db.org/network/P07101 |
| BioGRID | 112233 | https://thebiogrid.org/112233 |
| GTEx | TH | https://gtexportal.org/home/gene/TH |
| Human Protein Atlas | ENSG00000123472 | https://www.proteinatlas.org/ENSG00000123472-TH |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Tyrosine 3-monooxygenase activity | GO:0004511 |
| Molecular Function | Iron ion binding | GO:0005506 |
| Molecular Function | Tetrahydrobiopterin binding | GO:0034618 |
| Biological Process | Catecholamine biosynthetic process | GO:0042423 |
| Biological Process | Dopamine biosynthetic process | GO:0042416 |
| Biological Process | Response to hypoxia | GO:0001666 |
| Cellular Component | Cytosol | GO:0005829 |
| Cellular Component | Synapse | GO:0045202 |

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)

## References

[1] Wang, Y., Wang, C., Liu, M., Xu, W., Wang, S., Yuan, F., Luo, X., Xu, Q., Yin, R., Wang, A., Guo, M., Lin, L., Wang, C., Cheng, H., Liu, Z., Zhang, Y., Zeng, F., Yan, J., & Chen, Y. (2022). Segawa syndrome caused by TH gene mutation and its mechanism. *Frontiers in Genetics*. https://www.semanticscholar.org/paper/1f2d3f736db310e46684bd904ebba90c0799adc5

[2] Wan, M., Héjjas, K., Rónai, Z., Elek, Z., Sasvári-Székely, M., Champagne, F., Miklósi, Á., & Kubinyi, E. (2013). DRD4 and TH gene polymorphisms are associated with activity, impulsivity and inattention in Siberian Husky dogs. *Animal Genetics*. https://www.semanticscholar.org/paper/7a26e3cf96c4d005ad2d6b57b6ac64d84c76eb98

[3] Kubinyi, E., Vas, J., Héjjas, K., Rónai, Z., Brúder, I., Turcsán, B., Sasvári-Székely, M., & Miklósi, Á. (2012). Polymorphism in the Tyrosine Hydroxylase (TH) Gene Is Associated with Activity-Impulsivity in German Shepherd Dogs. *PLoS ONE*. https://www.semanticscholar.org/paper/1513d29b6a08f7e37457255b1be6238ed6fe82bb

[4] Polymeropoulos, M., Xiao, H., Rath, D. S., & Merril, C. R. (1991). Tetranucleotide repeat polymorphism at the human tyrosine hydroxylase gene (TH). *Nucleic Acids Research*. https://www.semanticscholar.org/paper/fc08fcbe7b3d4146245f5b20eadfdc1144137644

[5] Furukawa, Y., Graf, W., Wong, H., Shimadzu, M., & Kish, S. (2001). Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations. *Neurology*. https://www.semanticscholar.org/paper/9578ef27a07e16bed288ff05ceb3828149e201bd

[6] Fukuchi, M., Fujii, H., Takachi, H., Ichinose, H., Kuwana, Y., Tabuchi, A., & Tsuda, M. (2010). Activation of tyrosine hydroxylase (TH) gene transcription induced by brain-derived neurotrophic factor (BDNF) and its selective inhibition through Ca(2+) signals evoked via the N-methyl-D-aspartate (NMDA) receptor. *Brain Research*. https://www.semanticscholar.org/paper/0fe3486da13d9bde6261eaa4be90e84c33906370

[7] Wei, J., Ramchand, C., & Hemmings, G. (1995). Association of polymorphic VNTR region in the first intron of the human TH gene with disturbances of the catecholamine pathway in schizophrenia. *Psychiatric Genetics*. https://www.semanticscholar.org/paper/e068e49cba32ad61fe80035547fcba8128101275

[8] Takeuchi, Y., Hashizume, C., Chon, E., Momozawa, Y., Masuda, K., Kikusui, T., & Mori, Y. (2005). Canine tyrosine hydroxylase (TH) gene and dopamine beta-hydroxylase (DBH) gene: their sequences, genetic polymorphisms, and diversities among five different dog breeds. *Journal of Veterinary Medical Science*. https://www.semanticscholar.org/paper/b9b4ac48ac63314fc4bc3d613531b4ab4e977487

[9] Sutherland, G., Mellick, G., Newman, J. R. B., Double, K., Stevens, J., Lee, L., Rowe, D., Silburn, P., & Halliday, G. (2008). Haplotype analysis of the IGF2-INS-TH gene cluster in Parkinson's disease. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*. https://www.semanticscholar.org/paper/e1a8a8a4002cfc23ce566db5716378d19f1e5860

[10] Wang, L., Li, B., Lu, X., Zhao, Q., Li, Y., Ge, D., Li, H., Zhang, P., Chen, S., Chen, R., Qiang, B., & Gu, D. (2008). A functional intronic variant in the tyrosine hydroxylase (TH) gene confers risk of essential hypertension in the Northern Chinese Han population. *Clinical Science*. https://www.semanticscholar.org/paper/9732d401389ec6815a0081b6bc0fbc25d5010d20

[11] Rodríguez, S., Gaunt, T. R., O'Dell, S., Chen, X., Gu, D., Hawe, E., Miller, G., Humphries, S., & Day, I. (2004). Haplotypic analyses of the IGF2-INS-TH gene cluster in relation to cardiovascular risk traits. *Human Molecular Genetics*. https://www.semanticscholar.org/paper/59f91b78ab5bc98de6413ef669d058410924565b

[12] Shah, P., Nankova, B., Parab, S., & La Gamma, E. F. (2006). Short chain fatty acids induce TH gene expression via ERK-dependent phosphorylation of CREB protein. *Brain Research*. https://www.semanticscholar.org/paper/0c473e52e4cd8a548bddf5a018f885df8d6e6179

[13] Trembleau, A., & Bloom, F. (1998). Subcellular localization of tyrosine hydroxylase (TH) gene transcripts: New insights into the pattern of TH gene expression in the locus coeruleus under pharmacological stimulation. *Biology of the Cell*. https://www.semanticscholar.org/paper/db01968cb363aeafcc4849f44386af9982f7a376

[14] Zheng, J., He, C., Chen, S., Yan, X., Guo, M., Wang, M., Yu, Y., Yang, Z., & Mai, B. (2017). Disruption of thyroid hormone (TH) levels and TH-regulated gene expression by polybrominated diphenyl ethers (PBDEs), polychlorinated biphenyls (PCBs), and hydroxylated PCBs in e-waste recycling workers. *Environment International*. https://www.semanticscholar.org/paper/2d6a91fd795feebe9456af698a11c90230951c53

[15] Nagatsu, T., & Nagatsu, I. (2016). Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects. *Journal of Neural Transmission*. https://www.semanticscholar.org/paper/484aca090cdbbb5c51ea673e78022716a8cb18e0

[16] Zheng, W., & Flavell, R. (1997). The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. *Cell*. https://www.semanticscholar.org/paper/3eae8ed2073dbe6ef94c4c54e762c1e9ab96fa31

[17] Liang, Y., Jiao, S., Wang, M., Yu, H., & Shen, Z. (2019). A CRISPR/Cas9-based genome editing system for Rhodococcus ruber TH. *Metabolic Engineering*. https://www.semanticsch